Vasculitis & polymyalgia rheumatica
Is there a window of opportunity in the treatment of giant cell arteritis with tocilizumab? Multicenter study of 471 patients
Authors' conclusion
Although no clear window of opportunity was identified using the classic cut-off for TCZ initiation in GCA (≤6 weeks), an earlier initiation of TCZ after diagnosis appears to be associated with a higher likelihood of remission in patients with GCA.
Study context
- Population
- Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) (72.6 % female; mean age 73.5 ± 9 years)
- Participants
- 471 patients
- Exposure
- TCZ started ≤6 weeks from diagnosis vs >6 weeks
- Newly Diagnosedn = 91
- Refractoryn = 380reference
- Outcome
- EULAR-defined remission, cumulative organ damage and relapse rates by timing of TCZ initiation
- Follow-up
- 24 months
Methodological detailsmultivariable regression adjusted for potential confounders
- Multivariable regression adjusted for potential confounders
Main finding
As reported in the abstract
EULAR remission, cumulative organ damage, relapse rates
- No significant differences between Newly Diagnosed and Refractory in EULAR remission, cumulative organ damage or relapse rates
Observational data: associations, not effects.
Further findings
EULAR remission at 24 months by time from GCA diagnosis to TCZ initiation (continuous variable)
| OR for EULAR remission at 24 months per unit increase in time from diagnosis to TCZ initiation (95 % CI) | P value | ||
|---|---|---|---|
| Time from GCA diagnosis to TCZ initiation (continuous)Shorter time to TCZ initiation associated with remission | 0.983 (0.967–0.999) | P = 0.035 | |
| 0.512OR for EULAR remission at 24 months per unit increase in time from diagnosis to TCZ initiation (log scale) |
- EULAR remission at 24 months by time from GCA diagnosis to TCZ initiation (continuous variable): multivariable regression adjusted for potential confounding factors
Organ damage and relapses by time from GCA diagnosis to TCZ initiation (continuous variable)
- No significant associations found for organ damage or relapses
Original publication
Is there a window of opportunity in the treatment of giant cell arteritis with tocilizumab? Multicenter study of 471 patients. Semin Arthritis Rheum. Published 6 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →